GlassScriptPhysician profile
Vanessa Foxworth
NPI 1578054037
$2,910.88
in general payments reported to CMS, 2019-2025
26 companies · $301 in 2025
The $301 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $215 · 2020: $120 · 2021: $282 · 2022: $624 · 2023: $963 · 2024: $406 · 2025: $301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,670.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,669.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $436.69 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $381.26 | 2021-2024 | |
| Lilly USA, LLC | $329.15 | 2021-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $273.08 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $181.84 | 2019-2021 | |
| Amgen INC. | $143.85 | 2022-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $139.86 | 2022-2024 | Breztri, Farxiga, Airsupra |
| Exact Sciences Corporation | $120.67 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $114.51 | 2024-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $94.21 | 2019-2023 | |
| Neurocrine Biosciences, INC. | $90.86 | 2019 | |
| Nestle Healthcare Nutrition INC. | $74.29 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $70.34 | 2021-2023 | Gardasil 9, Vaxneuvance |
| Pfizer INC. | $61.84 | 2019 | |
| Idorsia Pharmaceuticals US INC | $57.88 | 2023 | Quviviq |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $57.42 | 2021-2022 | |
| Astellas Pharma US INC | $51.14 | 2023-2025 | Veozah |
| Coloplast Corp | $36.93 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $35.94 | 2022 | |
| Organon LLC | $33.15 | 2025 | Nexplanon |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.63 | 2023 | Jardiance, Synjardy, Tradjenta |
| Amneal Pharmaceuticals LLC | $24.97 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $24.70 | 2024 | Rexulti |
| Novartis Pharmaceuticals Corporation | $16.82 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $14.36 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.49 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanessa Foxworth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.